DAWN Day One Biopharmaceuticals
- 16.000
- -0.380-2.32%
- 15.850
- -0.150-0.94%
Day One Biopharmaceuticals News
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Analysts' Top Healthcare Picks: Viridian Therapeutics (VRDN), Day One Biopharmaceuticals (DAWN)
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Day One Biopharm Price Target Cut to $40.00/Share From $50.00 by HC Wainwright & Co.
Day One Biopharm Price Target Cut to $40.00/Share From $50.00 by HC Wainwright & Co.
Day One Biopharm 1Q Loss/Shr 72c >DAWN
Day One Biopharm 1Q Loss/Shr 72c >DAWN
Day One Biopharmaceuticals | 10-Q: Quarterly report
Day One Biopharmaceutical Q1 2024 GAAP EPS $(0.72) Misses $(0.66) Estimate
Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.66) by 9.09 percent.
Press Release: Day One Reports First Quarter 2024 Financial Results and Corporate Progress
Day One Reports First Quarter 2024 Financial Results and Corporate Progress OJEMDA(TM) (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pe
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
Jeremy Bender, Director, Chief Executive Officer, on May 01, 2024, sold 79,211 shares in Day One Biopharmaceuticals (DAWN) for $1,415,707. Following the Form 4 filing with the SEC, Bender has control
Insider Sale at Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$1.42 Million in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Bender Jeremy sold 79,211 shares of common stock on May 1, 2, 3, 2024 at an average price of $17.8726 for a total value of $1.42 million.Source: Announcem
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$1.08 Million in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer York Charles N II sold 60,461 shares of common stock on May 1, 2, 3, 2024 at an average price of $17.8824 for a total value of $1.08 million.Source: Annou
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)
Form 144 | Day One Biopharmaceuticals(DAWN.US) Officer Proposes to Sell 2.05 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 1, $Day One Biopharmaceuticals(DAWN.US)$ Officer JEREMY BENDER intends to sell 120K shares of its common stock on May 1, with a total market value of approximately $2.05 mi
Form 144 | Day One Biopharmaceuticals(DAWN.US) Officer Proposes to Sell 1.37 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 1, $Day One Biopharmaceuticals(DAWN.US)$ Officer CHARLES YORK intends to sell 80,000 shares of its common stock on May 1, with a total market value of approximately $1.37 m
FDA Approval Gives Day One Biopharmaceuticals (NASDAQ:DAWN) More Room to Run
Pediatric Brain Tumor Foundation Celebrates FDA Approval of Day One Biopharmaceuticals' OJEMDA, New Treatment for Common Pediatric Brain Tumor Type
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- The Pediatric Brain Tumor Foundation (PBTF) is pleased to celebrate the FDA's approval of Day One Biopharmaceuticals' OJEMDA (tovorafenib), a new therapy for the treatment of
Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.
Needham: Reiterates the Day One Biopharmaceutics (DAWN.US) rating and adjusted from buy to buy rating, target price of $33.00.
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101) IN PARTNERSHIP WITH PNOC SCIENTIFIC CONSORTIUM AND DAY ONE BIOPHARMACEUTICALS
The Pediatric Neuro-Oncology Consortium Foundation (PNOC Foundation), a platinum rated non-profit dedicated to supporting advancements in childhood...
Analysis
Price Target
No Data
